Abstract
The implementation of personalized or precision medicine involves developing therapeutic agents to fit a patient’s molecular profile. Biomarkers are defined as “any characteristic that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological response to a therapeutic intervention.” Biomarkers typically undergo discovery and development phases. In biomarker discovery or development, the laboratory assays for the markers must be standardized in a way that results are comparable among a variety of laboratories. The importance of a standardized, well-controlled approach to biospecimen management and biobank operation to biomarker discovery is also well-established. A multitude of factors including preanalytical variables can affect biospecimen quality and as a result the analyses necessary to discover and validate biomarkers. Biospecimens of consistent quality are necessary as critical starting materials for biomarker discovery and the clinical assay development processes. Biobanks that serve as sources of biospecimens for biomarker studies should adhere to best practices such as those developed by international biobanking organizations. The importance of biobanking standards in biomarker discovery and development has also been recognized in several sets of recommendations and guidelines for authors, reviewers, and editors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nass SJ, Moses HL (2007) Cancer biomarkers. The promises and challenges of improving detection and treatment. The National Academies Press, Washington, DC
Khleif SN, Doroshow JH, Hait WN (2010) AACR-FDA-NCI cancer biomarkers collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16:3299–3318
Taube SE, Clark GM, Dancey JE et al (2009) A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 101:1453–1463
Poste G, Carbone DP, Parkinson DR et al (2012) Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 18:1515–1523
The Cancer Genome Atlas. US National Human Genome Research Institute: http://cancergenome.nih.gov/abouttcga/overview. Accessed 15 Feb 2021
The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068
The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615
Hewitt SM, Badve SS, True LD (2012) Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy. Clin Cancer Res 18:1524–1530
Zlobec I, Koelzer VH, Dawson H, Aurel Perren A, Lugli A et al (2013) Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types. J Transl Med 11:104–110
Zenobi R (2013) Single-cell mebabolomics: analytical and biological perspectives. Science 342:1201–1211
Vaught J, Henderson MK, Compton CC (2012) Biospecimens and biorepositories: from afterthought to science. Cancer Epidemiol Biomarkers Prev 21:253–255
US National Cancer Institute Biorepositories and Biospecimen Research Branch. http://www.biospecimens.cancer.gov. Accessed 15 Feb 2021
BBMRI (Biobanking and Biomolecular Resources Research Infrastructure). http://bbmri.eu/. Accessed 17 Dec 2013
Standardisation and improvement of generic pre-analytical tools and procedures for in-vitro diagnostics (SPIDIA). http://www.spidia.eu/. Accessed 15 Feb 2021
US National Cancer Institute Biorepositories and Biospecimen Research Branch, Biospecimen Research Network Symposia. http://biospecimens.cancer.gov/meeting/brnsymposium/. Accessed 15 Feb 2021
International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group Publications. http://www.isber.org/?page=WGP. Accessed 15 Feb 2021
Engel KB, Moore HM (2011) Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 135:537–543
Hewitt SM, Lewis FA, Cao Y et al (2008) Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 132:1929–1935
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
ASCO–CAP HER2 Test Guideline Recommendations. Summary of guideline 2007 and 2013 recommendations. http://www.cap.org/apps/docs/committees/immunohistochemistry/summary_of_recommendations.pdf. Accessed 15 Feb 2021
Rollins G (2013) ASCO/CAP update HER2 testing guidelines. Clin Lab News. http://www.aacc.org/publications/cln/2013/december/Pages/HER2-Testing.aspx. Accessed 15 Feb 2021
Vaught J, Kelly A, Hewitt R (2009) A review of international biobanks and networks: success factors and key benchmarks. Biopreserv Biobank 7:143–150. https://doi.org/10.1089/bio.2010.0003
McShane LM, Altman DG, Sauerbrei W, et al.; for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 41:1690–1696
Moore HM, Kelly A, Jewell SD et al (2011) Biospecimen reporting for improved study quality (BRISQ). Biopreserv Biobank 9:57–70. https://doi.org/10.1089/bio.2010.0036
Cheah S, Dee S, Cole A, Matzke L, O’Donoghue S, Watson PH (2012) An online tool for improving biospecimen data element reporting. Biopreserv Biobank 10:501–510. https://doi.org/10.1089/bio.2012.0033
National Cancer Institute Clinical Assay Development Program. https://cdp.cancer.gov/scientific_programs/pacct/cadp.htm. Accessed 15 Feb 2021
Williams PM, Lively TG, Jessup JM et al (2012) Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res 18:1531–1539
College of American Pathologists Biorepository Accreditation Program presentation. http://biospecimens.cancer.gov/meeting/brnsymposium/2012/docs/Day2_Denise_Driscoll_Presentation.pdf. Accessed 15 Feb 2021
International Society for Biological and Environmental Repositories (ISBER). http://www.isber.org. Accessed 15 Feb 2021
European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB). http://www.esbb.org. Accessed 15 Feb 2021
Rothman N, Hainaut P, Schulte P, et al., editors 2011 Molecular epidemiology: principles and practices. International Agency for Research on Cancer Publication Number 163, Lyon
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vaught, J. (2021). Biobanking for Biomarker Discovery. In: Hainaut, P., Vaught, J., Zatloukal, K., Pasterk, M. (eds) Biobanking of Human Biospecimens. Springer, Cham. https://doi.org/10.1007/978-3-030-55901-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-55901-4_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-55900-7
Online ISBN: 978-3-030-55901-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)